Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

Scientists believe this drug will be the first of a new wave of similar medications, ones that are both nonaddictive and ...

Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive ...

RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of ...

Vertex's medication, named Journavx, is seen as a major development in the ongoing effort to provide effective pain management solutions without the harmful consequences associated with opioid ...

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain for adults.

The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...

A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.

AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...

Credit: Vertex The active ingredient in Journavx is suzetrigine, a sodium channel blocker. The use of Journavx for moderate to severe pain has not been studied beyond 14 days. The Food and Drug ...